{"drugs":["Meruvax II","Rubella Virus Vaccine, Live"],"mono":{"0":{"id":"522960-s-0","title":"Generic Names","mono":"Rubella Virus Vaccine, Live"},"1":{"id":"522960-s-1","title":"Dosing and Indications","sub":{"0":{"id":"522960-s-1-4","title":"Adult Dosing","mono":"<ul><li>Merck has decided to stop production of MERUVAX(R) II (Rubella Virus Vaccine Live) and will continue to manufacture only the combination vaccine.<\/li><li><b>Rubella; Prophylaxis:<\/b> 0.5 mL SUBQ x 1 dose<\/li><\/ul>"},"1":{"id":"522960-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Merck has decided to stop production of MERUVAX(R) II (Rubella Virus Vaccine Live) and will continue to manufacture only the combination vaccine.<\/li><li>safety and effectiveness in infants below the age of 12 mo have not been established<\/li><li><b>Rubella; Prophylaxis:<\/b> (12 mo and older) 0.5 mL SUBQ x 1 dose<\/li><\/ul>"},"3":{"id":"522960-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Merck has decided to stop production of MERUVAX(R) II (Rubella Virus Vaccine Live) and will continue to manufacture only the combination vaccine [1].<\/li><li>Rubella; Prophylaxis<\/li><\/ul>"}}},"3":{"id":"522960-s-3","title":"Contraindications\/Warnings","sub":[{"id":"522960-s-3-9","title":"Contraindications","mono":"<ul><li>Active febrile infection<\/li><li>Acute febrile illness (eg, febrile respiratory illness)<\/li><li>Active, untreated tuberculosis<\/li><li>Blood dyscrasias, leukemia, lymphomas, bone marrow malignancy<\/li><li>Family history of congenital or hereditary immunodeficiency<\/li><li>History of anaphylactic reactions to topical or systemic neomycin<\/li><li>Hypersensitivity to the vaccine components, including gelatin<\/li><li>Primary or acquired immunodeficiency including immunocompromised HIV<\/li><li>Immunosuppressive therapy (eg, corticosteroids, radiation, alkylating agents, antimetabolites)<\/li><li>Pregnancy<\/li><li>Pregnancy should be avoided for 28 days postvaccination based on Advisory Committee on Immunization Practices (ACIP) recommendations (Anon, 2001); pregnancy should be avoided for 3 months postvaccination based on manufacturer recommendations<\/li><\/ul>"},{"id":"522960-s-3-10","title":"Precautions","mono":"<ul><li>Defer vaccination at least 3 months following blood or plasma transfusions and administration of immune globulin, with the exception of postpartum vaccination of women who have received Rho(D) immune globulin and are susceptible to rubella; vaccination should NOT be delayed<\/li><li>Extremely remote risk for transmission of viral diseases<\/li><li>Fever may occur following vaccination<\/li><li>History of contact dermatitis to neomycin<\/li><li>HIV-infected patients<\/li><li>Special care should be taken to ensure that the injection does not enter a blood vessel<\/li><li>Temporary depression of tuberculin skin test sensitivity<\/li><li>Current thrombocytopenia<\/li><\/ul>"},{"id":"522960-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"522960-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breast-feeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"522960-s-4","title":"Drug Interactions","sub":{"1":{"id":"522960-s-4-14","title":"Major","mono":"<ul><li>Aclarubicin (established)<\/li><li>Adalimumab (theoretical)<\/li><li>Aldesleukin (established)<\/li><li>Alemtuzumab (established)<\/li><li>Altretamine (established)<\/li><li>Amonafide (established)<\/li><li>Amsacrine (established)<\/li><li>Asparaginase (established)<\/li><li>Azacitidine (established)<\/li><li>Azathioprine (established)<\/li><li>Bleomycin (established)<\/li><li>Broxuridine (established)<\/li><li>Busulfan (established)<\/li><li>Capecitabine (established)<\/li><li>Carboplatin (established)<\/li><li>Carmustine (established)<\/li><li>Certolizumab Pegol (theoretical)<\/li><li>Chlorambucil (established)<\/li><li>Cisplatin (established)<\/li><li>Cladribine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (theoretical)<\/li><li>Cytarabine (established)<\/li><li>Cytarabine Liposome (established)<\/li><li>Dacarbazine (established)<\/li><li>Dactinomycin (established)<\/li><li>Daunorubicin (established)<\/li><li>Daunorubicin Citrate Liposome (established)<\/li><li>Decitabine (established)<\/li><li>Docetaxel (established)<\/li><li>Doxifluridine (established)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Edatrexate (established)<\/li><li>Eflornithine (established)<\/li><li>Epirubicin (established)<\/li><li>Estramustine (established)<\/li><li>Etanercept (established)<\/li><li>Etoposide (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Floxuridine (established)<\/li><li>Fludarabine (established)<\/li><li>Fluorouracil (established)<\/li><li>Fotemustine (established)<\/li><li>Gallium Nitrate (established)<\/li><li>Gemcitabine (established)<\/li><li>Golimumab (theoretical)<\/li><li>Hydroxyurea (established)<\/li><li>Idarubicin (established)<\/li><li>Ifosfamide (established)<\/li><li>Immune Globulin (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (established)<\/li><li>Lomustine (established)<\/li><li>Mechlorethamine (established)<\/li><li>Melphalan (established)<\/li><li>Mercaptopurine (established)<\/li><li>Methotrexate (established)<\/li><li>Mitolactol (established)<\/li><li>Mitomycin (established)<\/li><li>Mitotane (established)<\/li><li>Mitoxantrone (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Oxaliplatin (established)<\/li><li>Paclitaxel (established)<\/li><li>Pegaspargase (established)<\/li><li>Pentostatin (established)<\/li><li>Pipobroman (established)<\/li><li>Pirarubicin (established)<\/li><li>Plicamycin (established)<\/li><li>Procarbazine (established)<\/li><li>Raltitrexed (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rituximab (established)<\/li><li>Secukinumab (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sirolimus (probable)<\/li><li>Streptozocin (established)<\/li><li>Tacrolimus (theoretical)<\/li><li>Teceleukin (established)<\/li><li>Tegafur (established)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (established)<\/li><li>Teriflunomide (theoretical)<\/li><li>Thioguanine (established)<\/li><li>Thiotepa (established)<\/li><li>Topotecan (established)<\/li><li>Trabectedin (theoretical)<\/li><li>Treosulfan (established)<\/li><li>Trimetrexate (established)<\/li><li>Trofosfamide (established)<\/li><li>Uracil Mustard (established)<\/li><li>Ustekinumab (theoretical)<\/li><li>Vinblastine (established)<\/li><li>Vincristine (established)<\/li><li>Vincristine Sulfate Liposome (established)<\/li><li>Vindesine (established)<\/li><li>Vinorelbine (established)<\/li><\/ul>"},"2":{"id":"522960-s-4-15","title":"Moderate","mono":"<ul><li>Abatacept (probable)<\/li><li>Cytomegalovirus Immune Globulin, Human (probable)<\/li><li>Hepatitis B Immune Globulin (probable)<\/li><li>Leflunomide (established)<\/li><li>Rabies Immune Globulin (probable)<\/li><li>Respiratory Syncytial Virus Immune Globulin, Human (probable)<\/li><li>Tetanus Immune Globulin (probable)<\/li><li>Vaccinia Immune Globulin, Human (probable)<\/li><li>Varicella-Zoster Immune Globulin (probable)<\/li><\/ul>"}}},"5":{"id":"522960-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site, Injection site pain, Rash<\/li><li><b>Immunologic:<\/b>Lymphadenopathy<\/li><li><b>Musculoskeletal:<\/b>Arthralgia, Women (12-26%), Arthritis, Women (12-26%), Myalgia, Women (12-26%)<\/li><li><b>Respiratory:<\/b>Common cold<\/li><li><b>Other:<\/b>Fever<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome<\/li><li><b>Hematologic:<\/b>Thrombocytopenia<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Encephalitis, Guillain-Barr  syndrome, Association with vaccine unlikely, Polyneuritis, Polyneuropathy<\/li><li><b>Ophthalmic:<\/b>Optic neuritis<\/li><\/ul>"},"6":{"id":"522960-s-6","title":"Drug Name Info","sub":{"0":{"id":"522960-s-6-17","title":"US Trade Names","mono":"Meruvax II<br\/>"},"2":{"id":"522960-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"522960-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"522960-s-7","title":"Mechanism Of Action","mono":"Systemic: Following subcutaneous injection, rubella virus vaccine live produces a modified, noncommunicable rubella infection and provides active immunity to rubella .<br\/>"},"9":{"id":"522960-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for SubQ use only; do not inject IV<br\/><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>do not give concurrently with immune globulin<\/li><li>mix with supplied diluent, give SubQ in outer aspect of upper arm<\/li><li>do not give less than one month before or after administration of other live virus vaccines<\/li><\/ul><\/li><\/ul>"},"13":{"id":"522960-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel female patients to use reliable contraception to avoid pregnancy for at least 3 months post-vaccination.<\/li><li>This vaccination should be deferred at least 3 months following blood or plasma transfusions and administration of immune globulin.<\/li><li>This product contains human albumin. Despite screening and testing, human plasma products carry a risk of transmitting infectious agents. Risks and benefits should be discussed with patient by healthcare professional.<\/li><li>This drug may cause arthralgia, arthritis, or myalgia in female patients. Drug may also cause lymphadenopathy or symptoms of the common cold.<\/li><li>Advise patient to report fever or signs\/symptoms of thrombocytopenia or Stevens-Johnson syndrome (flu-like symptoms, spreading red rash, or skin\/mucous membrane blistering).<\/li><li>Patient should also report signs\/symptoms of optic neuritis, polyneuritis, or polyneuropathy.<\/li><li>Tell patient to avoid other vaccines one month before or one month after having this vaccine, unless approved by healthcare professional.<\/li><\/ul>"}}}